- About
- Main Menu
- Main Menu
- Leadership Team
- Our History
- Capabilities
- Main Menu
- Main Menu
- Bioconjugates & Chemistry
- Biologics
- Resources
- Careers
- Contact
What are three key trends shaping the CDMO industry in 2023 and beyond? From the rise of antibody-drug conjugates (ADCs) to increasingly potent compounds and downstream development strategies, Abzena’s chief technical officer, Dr Louise Duffy, shares her thoughts with Contract Pharma.